ID   IGR-CaP1-R-caba
AC   CVCL_WM75
DR   cancercelllines; CVCL_WM75
DR   Wikidata; Q94314872
RX   PubMed=27198502;
CC   Selected for resistance to: ChEBI; CHEBI_63584; Cabazitaxel.
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Tyr126Cys (c.377A>G); ClinVar=VCV000458541; Zygosity=Unspecified (from parent cell line).
CC   Derived from site: In situ; Prostate; UBERON=UBERON_0002367.
DI   NCIt; C4863; Prostate carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_A018 ! IGR-CaP1
SX   Male
AG   58Y
CA   Cancer cell line
DT   Created: 24-05-19; Last updated: 19-12-24; Version: 8
//
RX   PubMed=27198502; DOI=10.15252/emmm.201506059; PMCID=PMC4931290;
RA   Al Nakouzi, Nader
RA   Wang, Chris Ke-Dong
RA   Beraldi, Eliana
RA   Jager, Wolfgang
RA   Ettinger, Susan
RA   Fazli, Ladan
RA   Nappi, Lucia
RA   Bishop, Jennifer L.
RA   Zhang, Fan
RA   Chauchereau, Anne
RA   Loriot, Yohann
RA   Gleave, Martin E.
RT   "Clusterin knockdown sensitizes prostate cancer cells to taxane by
RT   modulating mitosis.";
RL   EMBO Mol. Med. 8:761-778(2016).
//